Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$156.45 USD

156.45
13,991,025

+5.79 (3.84%)

Updated Aug 25, 2026 04:04 PM ET

After-Market: $156.65 +0.20 (0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (103 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kanishka Das headshot

Can Keytruda Sustain Merck's Growth Through the Rest of 2025?

by Kanishka Das

MRK banks on Keytruda's soaring sales and new oncology strategies to fuel 2025 growth, even as competition and patent loss loom.

Zacks Equity Research

GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?

by Zacks Equity Research

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP launch Yeztugo.

Zacks Equity Research

The Zacks Analyst Blog Highlights Merck, Palo Alto Networks, Freeport-McMoRan and Espey

by Zacks Equity Research

Analysts spotlight Merck, Palo Alto Networks, Freeport-McMoRan, and Espey as innovation, contract wins, and industry trends shape growth prospects.

Zacks Equity Research

AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs

by Zacks Equity Research

AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.

Mark Vickery headshot

Top Analyst Reports for Merck, Palo Alto & Freeport

by Mark Vickery

Merck leans on Keytruda growth and pipeline expansion, Palo Alto rides subscription security demand, and Freeport benefits from electrification-driven copper demand.

Ekta Bagri headshot

Exelixis Gains 15.6% YTD: How Should You Play the Stock?

by Ekta Bagri

EXEL rides on Cabometyx growth and zanzalintinib's trial success, but Q2 revenue miss and competition keep investor sentiment cautious.

Kinjel Shah headshot

PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?

by Kinjel Shah

Pfizer's new and acquired drugs record sales of $4.7B in H1 as COVID-products related volatility eases.

Ekta Bagri headshot

Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?

by Ekta Bagri

Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.

Zacks Equity Research

SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus

by Zacks Equity Research

Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.

Zacks Equity Research

Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?

by Zacks Equity Research

MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.